Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology Group
- 7 April 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (6) , 939-942
Abstract
Background Malnutrition is common at diagnosis and during treatment for sarcoma patients. Poor nutritional status is associated with increased risk of complications, particularly infections. We investigated the role of body mass index (BMI) on the incidence of surgical wound complications in patients with localized osteosarcoma treated on the Children's Oncology Group (COG) legacy trial, INT‐0133. Procedure Patients considered in this report had localized osteosarcoma, enrolled on COG trial INT‐0133, remained on protocol therapy to have definitive surgery 6–16 weeks after study entry, and had adequate height, weight, and surgical complication data for analysis. By protocol design, definitive surgical resection was planned for 10 weeks after induction chemotherapy. Wound complications within 30 days after definitive surgery were considered post‐operative. BMI was calculated at the start of neoadjuvant chemotherapy and expressed as age‐ and gender‐adjusted percentile. The incidence of wound complications was evaluated by logistic regression or Fisher's exact test. Results A total of 498 patients met criteria for analysis. Low BMI (≤10th percentile) was seen in 73 (14.7%), middle BMI (11th–94th percentile) in 382 (76.7%), and high BMI (≥95th percentile) in 43 (8.6%) patients. Wound infection or slough was seen in low BMI patients (OR = 2.0, P = 0.07) although the results did not reach statistical significance. Arterial thrombosis was more common in high BMI patients (OR = 9.4, P = 0.03). Conclusions Abnormal BMI at the start of treatment for localized osteosarcoma is associated with increased risk of post‐operative wound complications such as arterial thrombosis. Future studies should evaluate whether maintenance of age‐appropriate BMI reduces the risk of surgical complications. Pediatr Blood Cancer 2011; 57: 939–942.Keywords
This publication has 23 references indexed in Scilit:
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2008
- Children's Oncology Group (COG) Nutrition CommitteePediatric Blood & Cancer, 2008
- Nutritional Support During Radiotherapy for Head and Neck Cancer: The Role of Prophylactic Feeding Tube PlacementClinical Journal of Oncology Nursing, 2007
- Impact of nutrition on quality of life during cancerCurrent Opinion in Clinical Nutrition and Metabolic Care, 2007
- Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose MethotrexateJournal of Clinical Oncology, 2005
- The Role of Nutrition in the Management of Lower Extremity WoundsThe International Journal of Lower Extremity Wounds, 2005
- Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescentsThe American Journal of Clinical Nutrition, 2002
- 2000 CDC Growth Charts for the United States: methods and development.2002
- Nutritional status of children with solid tumorsCancer, 1999
- Malnutrition in children with cancer.Incidence and consequenceCancer, 1979